Encision Launches Next Generation of EnTouch(R) Handles for Advanced Laparoscopic Procedures
March 26 2008 - 6:52AM
PR Newswire (US)
BOULDER, Colo., March 26 /PRNewswire-FirstCall/ -- Encision Inc.
(AMEX:ECI) ("Encision" or the "Company") announced today that it is
launching its next generation of EnTouch handles for its AEM(R)
articulating laparoscopic instrument inserts. The new ES8200 and
ES8200L handles feature a stiffer shaft design to accommodate the
stresses generated by organ manipulation during advanced as well as
routine laparoscopic procedures. In addition, the new, easy to
operate rotation knob design allows a surgeon to lock the electrode
tip in the preferred orientation for the particular need during a
laparoscopic procedure. The EnTouch model ES8200 is 35cm in length
for normal size patients while the ES8200L is 45cm in length for
large patients and many bariatric procedures. "Our goal is to offer
the ultimate in patient safety along with best of class ergonomic
instruments for the surgeon performing laparoscopy," said Jack
Serino, Encision President & CEO. Handle sales represented
approximately 10% of the Company's revenue for its fiscal year
ended March 31, 2007. Encision Inc. designs, develops, manufactures
and markets innovative surgical devices that allow surgeons to
optimize technique and patient safety during a broad range of
surgical procedures. Based in Boulder, Colorado, the Company
pioneered the development of patented AEM Laparoscopic Instruments
to improve electrosurgery and reduce the chance for patient injury
in minimally invasive surgery. In accordance with the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995,
the Company notes that statements in this press release and
elsewhere that look forward in time, which include everything other
than historical information, involve risks and uncertainties that
may cause actual results to differ materially from those indicated
by the forward-looking statements. Factors that could cause the
Company's actual results to differ materially include, among
others, its ability to increase net sales through the Company's
distribution channels, insufficient quantity of new account
conversions, insufficient cash to fund operations, scale up
production to meet delivery obligations, delay in developing new
products and receiving FDA approval for such new products and other
factors discussed in the Company's filings with the Securities and
Exchange Commission. CONTACT: Marcia McHaffie, Encision Inc.,
303-444-2600, DATASOURCE: Encision Inc. CONTACT: Marcia McHaffie of
Encision Inc., +1-303-444-2600, Web site: http://www.encision.com/
Copyright
Encision (AMEX:ECI)
Historical Stock Chart
From Jul 2024 to Aug 2024
Encision (AMEX:ECI)
Historical Stock Chart
From Aug 2023 to Aug 2024